Levetiracetam
Material: | 1 ml serum |
Methods: |
Flüssigkeitschromatographie-Massenspektrometrie (LC-MS/MS) → LC-Tandem-Massenspektrometrie Ligandenassays → Enzym-Multiplied-Immunoassay (EMIT) |
Indication | Therapeutic drug monitoring |
Therapeutic range | 10 mg/l – 40 mg/l |
Please note | The effect mechanism of levetiracetam is still unknown. Known side effects are somnolence, asthenia, nausea, headaches, depression, diarrhea, vertigo and exanthema. In case of concurrent administration of bivaracetam, there may be cross-reactions in the immuneoassay. In this case, the request should be for “Levetiracetam – chromatographically, LC-MS/MS”. |
Accredited | ja |
More Results for the letter L
- Lipometabolism diagnostics (LIPID)
- fat metabolism diagnostics
- Lipoprotein (a) = Lp (a) (LPA)
- Listeriosis (KLIST, LISMON)
- Listeria monocytogenes
- Lithium (LI)
- LKM autoantibodies (LKM)
- autoantibodies to liver and kidney microsomes
- LMA autoantibodies (LMA)
- Liver membrane antigen autoantibodies
- Lorazepam (LORA)
- Lormetazepam (LORM)
- LSD (LSDU)
- Lysergic acid diethylamide
- Lupus coagulant activity (LUPAK)
- Lymphocyte differentiation (LYMPD, LYMPDG, TREG, TAKT)
- Immune status
- Lysozyme (LYSOZ)